Cangrelor (AR-C69931MX), an adenosine triphosphate analogue, is an intravenous, reversible and selective plateletP2Y12antagonist, with prompt and potent antiplatelet effects. Cangrelor directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor is also a nonspecificGPR17antagonist^[1][2].

Cangrelor tetrasodium has pK_bof 8.6-9.2 for hP2Y12 receptor^[3].

Cangrelor tetrasodium (10 mg/kg) not only significantly decreases BLM-induced release of inflammatory cytokines (PF4, CD40 L and MPO), but also decreases the increment of platelets, neutrophils and platelet-neutrophil aggregates in the fibrotic lung and in the peripheral blood of BLM-treated mice^[2].

776.36

C₁₇H₂₅Cl₂F₃N₅O₁₂P₃S₂

163706-06-7

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.